VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
VolitionRx reported Q1 2026 revenue of $1 million, representing a 300% year-over-year increase, signaling accelerating commercial adoption. The company submitted a manuscript for its Nu.Q Vet feline cancer test, which could unlock a $5 million milestone payment upon publication, and is actively discussing licensing deals with more than a dozen global diagnostic leaders.
Key figures
- Revenue
- 1000000
- Revenue Yoy
- 300%
- Vet tam
- $1.0+ billion
- Sepsis tam
- $3.8 billion
- Capture seq tam
- $23 billion
- Detecseps program value
- $7.3 million
- Feline milestone payment
- $5 million
- Total addressable market
- $27+ billion
- Feline lymphoma sensitivity
- 86%
- Feline lymphoma specificity
- 97%
- Early stage cancer sensitivity
- 95%
- Early stage cancer specificity
- 95%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.